

ASX: ALA

Arovella Therapeutics Limited
ACN 090 987 250

**ASX RELEASE**

30 May 2024

Notice under ASX Listing Rule 3.10A

Arovella Therapeutics Limited ACN 090 987 250 (**ALA** or **Company**), hereby advises pursuant to ASX Listing Rule 3.10A that 413,379 Ordinary Shares are due to be released from voluntary escrow on **30 June 2024**. These Ordinary Shares were issued for the provision of investor relation services in lieu of cash.

Details of the securities to be released from voluntary escrow are as follows:

Class / description	Ordinary Shares (Shares)
ASX code	ALA
Date of issue	10 January 2024
Number issued	413,379

Tim Luscombe
Company Secretary

NOTES TO EDITORS:**About Arovella Therapeutics Ltd**

Arovella Therapeutics Ltd (ASX: ALA) is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. Arovella's lead product is ALA-101. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. Arovella is also expanding into solid tumour treatment through its CLDN18.2-targeting technology licensed from Sparx Group. iNKT cells also contain an invariant T cell receptor (iTTCR) that targets α -GalCer bound CD1d, another antigen found on the surface of several cancer types. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient.

Glossary: **iNKT cell** – invariant Natural Killer T cells; **CAR** – Chimeric Antigen Receptor that can be introduced into immune cells to target cancer cells; **TCR** – T cell receptors are a group of proteins found on immune cells that recognise fragments of antigens as peptides bound to MHC complexes; **B-cell lymphoma** – A type of cancer that forms in B cells (a type of immune system cell); **CD1d** – Cluster of differentiation 1, which is expressed on some immune cells and cancer cells; **α GalCer** – alpha-galactosylceramide is a specific ligand for human and mouse natural killer T cells. It is a synthetic glycolipid.

For more information, visit www.arovella.com